Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Type of study
Language
Publication year range
1.
Tijdschr Gerontol Geriatr ; 40(1): 29-33, 2009 Feb.
Article in Dutch | MEDLINE | ID: mdl-19326700

ABSTRACT

Two patients presented with progressive cognitive impairment and parkinsonism related symptoms while being treated with sodium valproate. Both patients suffered from progressive cognitive decline and mobility disorders with an insidious onset over a period of months to years. After discontinuation of sodium valproate both debilitating symptoms resolved nearly completely. There is a growing prevalence and incidence of epilepsy above the age of 60 and a great number of these patients are on sodium valproate treatment. All clinicians treating elderly patients should be aware of the fact that this treatment can cause reversible cognitive decline and parkinsonism probably due to impairment of mitochondrial complex I function. Discontinuation of sodium valproate is strongly recommended in all patients with development of cognitive impairment or parkinsonism or both during sodium valproate treatment.


Subject(s)
Anticonvulsants/adverse effects , Cognition Disorders/chemically induced , Parkinson Disease, Secondary/chemically induced , Valproic Acid/adverse effects , Aged , Anticonvulsants/therapeutic use , Cognition Disorders/epidemiology , Epilepsy/drug therapy , Humans , Male , Parkinson Disease, Secondary/epidemiology , Recovery of Function , Valproic Acid/therapeutic use
2.
Tijdschr Gerontol Geriatr ; 37(2): 67-77, 2006 Apr.
Article in Dutch | MEDLINE | ID: mdl-16704019

ABSTRACT

In this article different aspects of chronic heart failure in old age are described. We mainly focus on the place of beta-blocker therapy in chronic heart failure. Beta-blockers are recommended for the treatment of stable chronic heart failure with left ventricular systolic dysfunction. There is additional information from recent studies that there is proven efficacy for beta-blocker therapy in patients with heart failure up to the age of 80 years. For patients with heart failure aged 80 and over the evidence to prescribe beta-blockers is limited. However, it is known that also in very elderly patients beta-blocker therapy is well tolerated. In patients with heart failure with preserved systolic ventricular function there is still no evidence that there is a beneficial effect of beta-blockers. It is still not clear if there are differences between beta-blocking agents. Of all beta-blockers, only bisoprolol, carvedilol, nebivolol and metoprolol CR are proven effective in stable chronic heart failure with impaired left ventricular systolic function and can be recommended in elderly patients on standard treatment with diuretics and ACE inhibition.


Subject(s)
Adrenergic beta-Antagonists/therapeutic use , Heart Failure/drug therapy , Adrenergic beta-Antagonists/adverse effects , Age Factors , Aged , Aged, 80 and over , Chronic Disease , Female , Humans , Male , Treatment Outcome , Ventricular Dysfunction, Left/drug therapy
SELECTION OF CITATIONS
SEARCH DETAIL
...